

# Does the active transport of albumin play a role on sorafenib distribution in human pulmonary artery endothelial cells?

G. Bonnefois<sup>1</sup>, L. Payen<sup>2</sup>, J. Guillon<sup>1</sup>, G. Freyer<sup>1</sup>, I. Rouvet<sup>3</sup>, M. Tod<sup>1,4</sup>

(1)EA3738 Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon-Sud, Oullins France; (2)Institut des Sciences Pharmaceutiques et Biologiques, Lyon France; (3)Centre de biotechnologie cellulaire, Centre de Biologie et de Pathologie Est - CHU Lyon, 69677 Bron, France; (4)Hospices Civils de Lyon, France.

## Background

Albumin is able to penetrate into endothelial cells. Active influx is mediated by albumin [1], active efflux by FcRn [2]. The impact of intracellular albumin on intracellular drug concentration is unknown. PBPK models should take this into account.

## Objective:

To study the impact of albumin transport on drug intracellular concentration in vitro. Probe: Sorafenib, an anti-angiogenic drug highly bound to albumin.


## Material and Methods

### Experimental design :

Cultures of human endothelial cells with different albumin and sorafenib concentrations. Measurement of intracellular sorafenib by LC-MS/MS.

### Structural Model (fig 1.)

A mixed-effect regression model was fitted to the apparent intracellular sorafenib concentrations to estimate the parameters characterizing sorafenib and albumin penetration into cells (NONMEM 7).



Kd was measured by fluorescence quenching.

Different transports were considered :

- A passive diffusion :  $CL_d$
- An active transport :  
If non linear :  $V_m$  and  $K_m$   
If linear :  $CL_{AB}$  and  $CL_{BA}$

The analytical process results in a factor of dilution ( $\alpha$ ) of the intracellular content.

## Results

Table I. Parameter estimates with the final model

Parameter	Point Estimate (SE)
Kd ( $\mu\text{M}$ )	0.2 (fixed)
$CL_{AB}/CL_{BA}$	0.141 (0.040)
Median ( $\alpha$ ) Experiment 1, 2	163 (34) 338 (65)
CV( $\alpha$ )	0.62 (0.26)
CV( $\epsilon$ )	0.33 (0.04)

Intracellular concentration of albumin is 14 % of extracellular concentration.

Fig 2. Goodness-of-fit of the model





Fig 3. Individual predictions versus observed sorafenib concentrations





Fig 4. Impact of albumin transport on sorafenib coefficient of partition ( $K_p$ ) into endothelial cells.



## Conclusion

- Penetration of albumin was shown to behave as a linear process in our conditions.
- The  $K_p$  of sorafenib into endothelial cells was greatly increased by albumin transport, a fact that must be accounted for in mechanistic PBPK models.
- The impact of albumin transcytosis on intratumoral distribution of sorafenib remains to be studied.

## References

1. John TA et al. *Am J Physiol Lung Cell Mol Physiol* 284(1):L187-96.
2. Chaudhury C et al. (2003). *J Exp Med*. 197(3):315-22.